Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum Sells 27,098 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 27,098 shares of the business’s stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $30.08, for a total value of $815,107.84. Following the sale, the chief executive officer now directly owns 27,918 shares in the company, valued at $839,773.44. This trade represents a 49.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Andrew Dudum also recently made the following trade(s):

• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.00, for a total value of $9,000.00.
• On Thursday, January 16th, Andrew Dudum sold 36,460 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.09, for a total transaction of $987,701.40.
• On Monday, December 16th, Andrew Dudum sold 78,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.62, for a total transaction of $2,314,121.74.
• On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The stock was sold at an average price of $33.38, for a total transaction of $1,118,663.94.
• On Tuesday, November 5th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.88, for a total transaction of $3,943,981.44.

Hims & Hers Health Stock Down 0.0 %

Shares of Hims & Hers Health stock opened at $30.89 on Friday. Hims & Hers Health, Inc. has a 12-month low of $8.51 and a 12-month high of $35.02. The stock has a market capitalization of $6.75 billion, a P/E ratio of 70.20 and a beta of 1.31. The stock has a 50 day moving average price of $28.22 and a two-hundred day moving average price of $22.18.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Hims & Hers Health’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.04) EPS. Sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors have recently made changes to their positions in HIMS. Means Investment CO. Inc. boosted its stake in Hims & Hers Health by 23.5% during the 4th quarter. Means Investment CO. Inc. now owns 50,040 shares of the company’s stock valued at $1,210,000 after purchasing an additional 9,508 shares during the period. Ausbil Investment Management Ltd acquired a new stake in shares of Hims & Hers Health in the fourth quarter worth $127,000. Genesee Capital Advisors LLC bought a new position in Hims & Hers Health during the fourth quarter worth $889,000. Perigon Wealth Management LLC bought a new position in Hims & Hers Health during the fourth quarter worth $337,000. Finally, Pacer Advisors Inc. acquired a new position in Hims & Hers Health during the 4th quarter valued at $374,000. 63.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on HIMS shares. Piper Sandler lifted their price target on Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a report on Monday, January 6th. Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their target price for the company from $32.00 to $18.00 in a report on Thursday, November 14th. TD Cowen restated a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Finally, Morgan Stanley began coverage on shares of Hims & Hers Health in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 target price for the company. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $25.13.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.